Phase I study of a carboplatin-etoposide combination in advanced thoracic cancer.
作者： Elias Tueni , Jean-Paul Sculier , Jean Klastersky
DOI: 10.1016/0277-5379(88)90143-5
关键词:
摘要: Abstract We conducted a phase I trial with the combination carboplatin (CBDCA)-etoposide (VP- 16 ) in thoracic cancer. CBDCA, at starting dose of 300 mg/m 2 d 1 , was associated fixed VP- ( 100 1–3 ). Escalation doses permitted after three patients entered each level without grade IV toxicity. As expected, hematologic toxicity limiting factor. Severe myelosuppression (grade IV) occurred out four treated 350 . Only 19 325 exhibited reversible Other toxicities were mild and acceptable. Among 15 evaluable showed partial response. Two responders have previously had progression while receiving cisplatin etoposide. The recommended to be is thus
ulb.ac.be
core.ac.uk
sci-hub.se 参考文章(10)
Jean Klastersky, Therapy with cisplatin and etoposide for non-small-cell lung cancer. Seminars in Oncology. ,vol. 13, pp. 104- 114 ,(1986)
Jean Klastersky, E. Longeval, Robert De Jager, High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: A phase II clinical trial of the EORTC lung cancer working party (Belgium) Cancer treatment reports. ,vol. 64, pp. 1341- 1346 ,(1980)
M Rozencweig, C Nicaise, M Beer, N Crespeigne, M Van Rijmenant, L Lenaz, Y Kenis, Phase I study of carboplatin given on a five-day intravenous schedule. Journal of Clinical Oncology. ,vol. 1, pp. 621- 626 ,(1983) , 10.1200/JCO.1983.1.10.621
A. H. Calvert, S. J. Harland, D. R. Newell, Z. H. Siddik, A. C. Jones, T. J. McElwain, S. Raju, E. Wiltshaw, I. E. Smith, J. M. Baker, M. J. Peckham, K. R. Harrap, Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II Cancer Chemotherapy and Pharmacology. ,vol. 9, pp. 140- 147 ,(1982) , 10.1007/BF00257742
J Klastersky, J P Sculier, P Ravez, P Libert, J Michel, G Vandermoten, P Rocmans, Y Bonduelle, M Mairesse, T Michiels, A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. Journal of Clinical Oncology. ,vol. 4, pp. 1780- 1786 ,(1986) , 10.1200/JCO.1986.4.12.1780
J L Mulshine, E Glatstein, J C Ruckdeschel, Treatment of non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 4, pp. 1704- 1715 ,(1986) , 10.1200/JCO.1986.4.11.1704
Ah Calvert, Ie Smith, M Gore, A PHASE-I HIGH-DOSE ESCALATION STUDY OF CARBOPLATIN Investigational New Drugs. ,(1987)
B D Evans, K S Raju, S J Harland, A H Calvert, E Wiltshaw, Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer treatment reports. ,vol. 67, pp. 997- 1000 ,(1983)
Huftalen Jb, Rose Wc, Schurig Je, Bradner Wt, Antitumor activity and toxicity of cisplatin analogs. Cancer treatment reports. ,vol. 66, pp. 135- 146 ,(1982)
Carboplatin and VP16-213 with radiotherapy (RT) as initial treatment for patients with small-cell lung-cancer (SCLC) Investigational New Drugs. ,vol. 5, pp. 62- 62 ,(1987) , 10.1007/BF00217667